Kiniksa (NASDAQ: KNSA) files Form 144 to sell 2,367 vested shares
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals (KNSA) submitted a Form 144 notice relating to the proposed sale of 2,367 Class A ordinary shares, reported in connection with a restricted stock lapse dated 04/01/2026. The filing lists Charles Schwab & Co., Inc. as the broker and references NASDAQ. A numeric line shows 45,900,637, which appears alongside other securities data in the excerpt.
Positive
- None.
Negative
- None.
Insights
Routine equity-compensation disposition notice tied to vested shares.
The filing shows a proposed sale under Form 144 for 2,367 Class A ordinary shares resulting from a restricted stock lapse dated 04/01/2026. Form 144 is a notice of intent to sell by an affiliate; it does not confirm execution or pricing.
Cash-flow treatment and proceeds recipients are not specified in the excerpt. Subsequent trading or Form 4/Form 5 filings would confirm actual sale details.